Chunfeng Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chunfeng Xu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Yuelian Liu
Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam and University of Amsterdam, Amsterdam Movement Sciences, 1081 LA Amsterdam, The Netherlands
9 shared publications - Dedong Yu
Department of Second Dental Center, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
3 shared publications Mingjie Wang
Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam and University of Amsterdam, Amsterdam, The Netherlands
3 shared publications- Mingjie Wang
Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, 1081 BT Amsterdam, The Netherlands
3 shared publications - Yiqun Wu
Department of Second Dental Center, Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
3 shared publications - Chang Du
Department of Biomaterials, School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China
2 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 3 (2)
Dental Brace Register for Accurate and Reproducible Bone Augmentation Evaluation in Dental Implantology
Accurate evaluation of bone augmentation is essential for surgical planning in dental implantology, and it is also crucial for validating the efficiency of bone augmentation approaches. However, the prevailing evaluation methods are complicated, time-consuming, operator-dependent, and hardly reproducible, undermining their feasibility and reliability in clinic. In response to these limitations, a registration apparatus composed of a transparent orthodontic retainer and radiographic markers was developed, enabling image superimposition before and after bone augmentation. A mandibular specimen underwent cone beam computed tomography (CBCT) scans at baseline, three, and six months, with and without the apparatus. Image registrations were independently performed by two examiners using the registration apparatus and two alternative methods. Root mean square (RMS) deviations were calculated to quantify registration accuracy. Statistical analyses were conducted using ANOVA and paired t-tests. Significant differences in RMS deviations were observed between the registration methods (p = 0.002), and using the registration apparatus achieved the lowest RMS deviation (0.055 ± 0.030 mm) and consistency at different timepoints (p = 0.856) and examiners (p = 0.441). This registration apparatus demonstrated high accuracy and reproducibility in bone augmentation evaluation, making it a potential reliable tool for quantitative evaluation of bone augmentation in dental implantology.
- 13 April 2026
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 3 (2)
Open AccessDental Brace Register for Accurate and Reproducible Bone Augmentation Evaluation in Dental Implantology
Accurate evaluation of bone augmentation is essential for surgical planning in dental implantology, and it is also crucial for validating the efficiency of bone augmentation approaches. However, the prevailing evaluation methods are complicated, time-consuming, operator-dependent, and hardly reproducible, undermining their feasibility and reliability in clinic. In response to these limitations, a registration apparatus composed of a transparent orthodontic retainer and radiographic markers was developed, enabling image superimposition before and after bone augmentation. A mandibular specimen underwent cone beam computed tomography (CBCT) scans at baseline, three, and six months, with and without the apparatus. Image registrations were independently performed by two examiners using the registration apparatus and two alternative methods. Root mean square (RMS) deviations were calculated to quantify registration accuracy. Statistical analyses were conducted using ANOVA and paired t-tests. Significant differences in RMS deviations were observed between the registration methods (p = 0.002), and using the registration apparatus achieved the lowest RMS deviation (0.055 ± 0.030 mm) and consistency at different timepoints (p = 0.856) and examiners (p = 0.441). This registration apparatus demonstrated high accuracy and reproducibility in bone augmentation evaluation, making it a potential reliable tool for quantitative evaluation of bone augmentation in dental implantology.
- 18 March 2026
- Published by Springer Nature in Oral and Maxillofacial Surgery
- Vol. 30 (1)
A Dynamic Navigation–Assisted Transcrestal Sinus Floor Elevation in Severely Atrophic Maxillae: A Descriptive Case Series
- 18 March 2026
- Published by Springer Nature in Oral and Maxillofacial Surgery
- Vol. 30 (1)
A Dynamic Navigation–Assisted Transcrestal Sinus Floor Elevation in Severely Atrophic Maxillae: A Descriptive Case Series
- Open Access
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 14, 1718616
In vitro evaluation of a self-positioning individualized titanium mesh for improved accuracy in guided bone regeneration
Introduction: Adequate bone volume and contour are essential for successful implant placement. This study evaluated the accuracy of a novel self-positioning three-dimensional printed individualized titanium mesh (3D-PITM) in guided bone regeneration (GBR). Methods: Ten identical maxillary phantoms with standardized defects were divided into an experimental self-positioning 3D-PITM group and a conventional 3D-PITM group. Pre- and postoperative CBCT scans were obtained for 3D reconstruction and superimposition. Deviations in augmented contours, screw placement, volumetric accuracy, and 2D cross-sectional augmentation were analyzed. Results: The self-positioning group showed significantly reduced deviation in augmentation contours (0.82 ± 0.07 mm vs. 1.02 ± 0.13 mm, P = 0.003), improved screw placement accuracy (0.10 ± 0.13 mm vs. 0.65 ± 0.32 mm, P = 0.026), and lower volumetric discrepancies. Two-dimensional evaluation confirmed greater vertical and horizontal accuracy in bone augmentation ( P = 0.021, P = 0.018). Conclusion: The self-positioning 3D-PITM achieved more accurate installation and predictable bone augmentation in vitro , suggesting potential clinical advantages for implant-supported rehabilitation.
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 14, 1718616
Open AccessIn vitro evaluation of a self-positioning individualized titanium mesh for improved accuracy in guided bone regeneration
Introduction: Adequate bone volume and contour are essential for successful implant placement. This study evaluated the accuracy of a novel self-positioning three-dimensional printed individualized titanium mesh (3D-PITM) in guided bone regeneration (GBR). Methods: Ten identical maxillary phantoms with standardized defects were divided into an experimental self-positioning 3D-PITM group and a conventional 3D-PITM group. Pre- and postoperative CBCT scans were obtained for 3D reconstruction and superimposition. Deviations in augmented contours, screw placement, volumetric accuracy, and 2D cross-sectional augmentation were analyzed. Results: The self-positioning group showed significantly reduced deviation in augmentation contours (0.82 ± 0.07 mm vs. 1.02 ± 0.13 mm, P = 0.003), improved screw placement accuracy (0.10 ± 0.13 mm vs. 0.65 ± 0.32 mm, P = 0.026), and lower volumetric discrepancies. Two-dimensional evaluation confirmed greater vertical and horizontal accuracy in bone augmentation ( P = 0.021, P = 0.018). Conclusion: The self-positioning 3D-PITM achieved more accurate installation and predictable bone augmentation in vitro , suggesting potential clinical advantages for implant-supported rehabilitation.
- Open Access
- 14 March 2025
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 2 (1)
Underestimated Roles of Osteocytes in Medication-Related Osteonecrosis of the Jaw
Perspective Underestimated Roles of Osteocytes in Medication-Related Osteonecrosis of the Jaw Chunfeng Xu and Yiqun Wu * Department of Second Dental Center, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Centre for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai 201900, China * Correspondence: yiqunwu@hotmail.com Received: 18 February 2025; Revised: 10 March 2025; Accepted: 11 March 2025; Published: 14 March 2025 Medication-related osteonecrosis of the jaw (MRONJ) is a grievous complication after the long-duration administration of some bone-modifying agents, mainly containing bisphosphonates (BPs), denosumab, angiogenesis inhibitors, immunosuppressors, glucocorticoids, and chemotherapeutics. Its prevalence is rare but mounting due to the widespread application of MRONJ-associated drugs in the aging population and cancer patients. Although MRONJ is excruciating, there has been no specific and efficient remedy for it. To date, the understanding of MRONJ is not thorough, and various theories on MRONJ have been proposed, among which impaired bone remodeling as a result of inhibited osteoclast generation and activity is the predominant one. However, the role of osteocytes in MRONJ has been omitted, given their crucial roles in governing bone metabolism: they not only communicate with osteoblasts for bone formation but also promote osteoclastogenesis.
- 14 March 2025
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 2 (1)
Open AccessUnderestimated Roles of Osteocytes in Medication-Related Osteonecrosis of the Jaw
Perspective Underestimated Roles of Osteocytes in Medication-Related Osteonecrosis of the Jaw Chunfeng Xu and Yiqun Wu * Department of Second Dental Center, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Centre for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai 201900, China * Correspondence: yiqunwu@hotmail.com Received: 18 February 2025; Revised: 10 March 2025; Accepted: 11 March 2025; Published: 14 March 2025 Medication-related osteonecrosis of the jaw (MRONJ) is a grievous complication after the long-duration administration of some bone-modifying agents, mainly containing bisphosphonates (BPs), denosumab, angiogenesis inhibitors, immunosuppressors, glucocorticoids, and chemotherapeutics. Its prevalence is rare but mounting due to the widespread application of MRONJ-associated drugs in the aging population and cancer patients. Although MRONJ is excruciating, there has been no specific and efficient remedy for it. To date, the understanding of MRONJ is not thorough, and various theories on MRONJ have been proposed, among which impaired bone remodeling as a result of inhibited osteoclast generation and activity is the predominant one. However, the role of osteocytes in MRONJ has been omitted, given their crucial roles in governing bone metabolism: they not only communicate with osteoblasts for bone formation but also promote osteoclastogenesis.
- Open Access
- 23 December 2024
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 1 (1) , 5
Impaired Osteoclastogenesis in Medication-Related Osteonecrosis and Potential Clinical Management with BMP-2
Review Chunfeng Xu 1, Yin Xiao 2, Yiqun Wu 1, Astrid Bakker 3 and Yuelian Liu 3,* 1 Department of Second Dental Center, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Centre for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai 201900, China 2 School of Medicine and Dentistry & Institute for Biomedicine and Glycomics, Griffith University, Gold Coast Campus, QC 4222, Australia 3 Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands * Correspondence: y.liu@acta.nl; Tel.: +31-205980626 Received: 5 November 2024; Revised: 18 December 2024; Accepted: 19 December 2024; Published: 23 December 2024 Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but severe, complication of applying inhibitors of osteoclasts, specifically bisphosphonates and the monoclonal antibody of receptor activator of nuclear factor kappa-Β ligand (RANKL), inhibitors of angiogenesis, and some chemotherapeutics. MRONJ is painful for the patients, while current treatments are unsatisfactory. Thus, it is imperative to understand the etiology and pathogenesis of MRONJ to improve treatment options and enable prevention. Various hypotheses have been proposed over the years to elucidate the pathogenesis of MRONJ. Noticeably, impaired osteoclastogenesis shines some light on novel preventive and treatment strategies. In this review, we summarized the current understanding of the role of osteoclastogenesis in the development of MRONJ and have put forward a hypothesis concerning the application of BMP2 in the clinical management strategy for MRONJ.
- 23 December 2024
- Published by Scilight Press Pty Ltd in Regenerative Medicine and Dentistry
- Vol. 1 (1) , 5
Open AccessImpaired Osteoclastogenesis in Medication-Related Osteonecrosis and Potential Clinical Management with BMP-2
Review Chunfeng Xu 1, Yin Xiao 2, Yiqun Wu 1, Astrid Bakker 3 and Yuelian Liu 3,* 1 Department of Second Dental Center, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Centre for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai 201900, China 2 School of Medicine and Dentistry & Institute for Biomedicine and Glycomics, Griffith University, Gold Coast Campus, QC 4222, Australia 3 Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands * Correspondence: y.liu@acta.nl; Tel.: +31-205980626 Received: 5 November 2024; Revised: 18 December 2024; Accepted: 19 December 2024; Published: 23 December 2024 Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but severe, complication of applying inhibitors of osteoclasts, specifically bisphosphonates and the monoclonal antibody of receptor activator of nuclear factor kappa-Β ligand (RANKL), inhibitors of angiogenesis, and some chemotherapeutics. MRONJ is painful for the patients, while current treatments are unsatisfactory. Thus, it is imperative to understand the etiology and pathogenesis of MRONJ to improve treatment options and enable prevention. Various hypotheses have been proposed over the years to elucidate the pathogenesis of MRONJ. Noticeably, impaired osteoclastogenesis shines some light on novel preventive and treatment strategies. In this review, we summarized the current understanding of the role of osteoclastogenesis in the development of MRONJ and have put forward a hypothesis concerning the application of BMP2 in the clinical management strategy for MRONJ.
- Open Access
- 3 November 2024
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 15 (11) , 327
Calcium Phosphate Loaded with Curcumin Prodrug and Selenium Is Bifunctional in Osteosarcoma Treatments
Although SeO32− ions have been loaded onto calcium phosphate to treat a wide range of cancers, the quest to promote bone tissue regeneration is still ongoing. Curcumin (cur), an herbal extraction, can selectively inhibit tumor cells and promote osteogenesis. In this study, SeO32− ions were co-precipitated in biomimetic calcium phosphate (Se@BioCaP), and modified curcumin prodrug (mcur) was adsorbed on diverse Se@BioCaP surfaces (mcur-Se@BioCaP-Ads). Co-precipitation yielded Se@BioCaP with a significantly higher Se content and exhibited a tailorable micro-/nanostructure. The favorable pH-responsive release of Se and mcur from mcur-Se@BioCaP-Ads showed a synergistic anticancer efficiency in OS cells, enhancing OS cell inhibition more than a single dose of them, which might be associated with ROS production in OS cells. In addition, increased alkaline phosphatase activity and calcium nodule formation in MC3T3-E1 pre-osteoblasts were also verified. These results suggest this novel mcur-Se@BioCaP-Ads has promising and widespread potential in OS treatments.
- 3 November 2024
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 15 (11) , 327
Open AccessCalcium Phosphate Loaded with Curcumin Prodrug and Selenium Is Bifunctional in Osteosarcoma Treatments
Although SeO32− ions have been loaded onto calcium phosphate to treat a wide range of cancers, the quest to promote bone tissue regeneration is still ongoing. Curcumin (cur), an herbal extraction, can selectively inhibit tumor cells and promote osteogenesis. In this study, SeO32− ions were co-precipitated in biomimetic calcium phosphate (Se@BioCaP), and modified curcumin prodrug (mcur) was adsorbed on diverse Se@BioCaP surfaces (mcur-Se@BioCaP-Ads). Co-precipitation yielded Se@BioCaP with a significantly higher Se content and exhibited a tailorable micro-/nanostructure. The favorable pH-responsive release of Se and mcur from mcur-Se@BioCaP-Ads showed a synergistic anticancer efficiency in OS cells, enhancing OS cell inhibition more than a single dose of them, which might be associated with ROS production in OS cells. In addition, increased alkaline phosphatase activity and calcium nodule formation in MC3T3-E1 pre-osteoblasts were also verified. These results suggest this novel mcur-Se@BioCaP-Ads has promising and widespread potential in OS treatments.
- Open Access
- 30 October 2024
- Published by Springer Nature in International Journal of Implant Dentistry
- Vol. 10 (1) , 1-11
In vivo validation of osteoinductivity and biocompatibility of BMP-2 enriched calcium phosphate cement alongside retrospective description of its clinical adverse events
Purpose: Although bone morphogenetic protein-2 (BMP-2) possesses potent osteoinductivity, there have been some concerns on the safety of BMP-2 and BMP-2-incorporated bone substitutes used for bone formation. On the other hand, BMP-2-loaded calcium phosphate cement (BMP-2@CPC) has been developed and used for bone regeneration in oral implantology. Therefore, this study aims to investigate this product's biocompatibility and clinical safety after being used in maxillofacial surgery. Materials and methods: A rat model was employed to assess the osteoinduction and biocompatibility of BMP-2@CPC. Further, a retrospective investigation was carried out: 110 patients who received BMP-2@CPC treatment after their maxillofacial surgery were recruited to describe relative adverse events. Results: In vivo, BMP-2@CPC showed a significantly higher mean bone volume density and osteoblasts volume density (15 ± 2% and 3 ± 1%)than those of the CPC group (p < 0.05) after being implanted in the dorsal area of rats. Regarding biocompatibility, the mean fibrous tissue volume density was significantly lower in the BMP-2@CPC group (20 ± 5% compared to 31 ± 6%, p = 0.026). The retrospective clinical study showed that only five mild/moderate adverse events were identified in four patients based on the medical records of 110 patients, including swelling, bony mass, and wound dehiscence. This adverse event occurrence was not affected by gender, age, the dose of filled materials, and operations in the study (p > 0.05). Conclusions: BMP-2-loaded CPC has osteoinductivity and more promising biocompatibility than pure CPC. However, its degradation is slower than CPC. The safety of BMP-2-loaded CPC with 0.5 or 1 mg BMP-2 is promising in oral maxillofacial surgery. Clinical implications: This study confirmed the promising safety of this BMP-2 incorporated CPC used in dental clinical practice, which can promote its reassuring application for dental implant placement in bone insufficient areas. Graphical
- 30 October 2024
- Published by Springer Nature in International Journal of Implant Dentistry
- Vol. 10 (1) , 1-11
Open AccessIn vivo validation of osteoinductivity and biocompatibility of BMP-2 enriched calcium phosphate cement alongside retrospective description of its clinical adverse events
Purpose: Although bone morphogenetic protein-2 (BMP-2) possesses potent osteoinductivity, there have been some concerns on the safety of BMP-2 and BMP-2-incorporated bone substitutes used for bone formation. On the other hand, BMP-2-loaded calcium phosphate cement (BMP-2@CPC) has been developed and used for bone regeneration in oral implantology. Therefore, this study aims to investigate this product's biocompatibility and clinical safety after being used in maxillofacial surgery. Materials and methods: A rat model was employed to assess the osteoinduction and biocompatibility of BMP-2@CPC. Further, a retrospective investigation was carried out: 110 patients who received BMP-2@CPC treatment after their maxillofacial surgery were recruited to describe relative adverse events. Results: In vivo, BMP-2@CPC showed a significantly higher mean bone volume density and osteoblasts volume density (15 ± 2% and 3 ± 1%)than those of the CPC group (p < 0.05) after being implanted in the dorsal area of rats. Regarding biocompatibility, the mean fibrous tissue volume density was significantly lower in the BMP-2@CPC group (20 ± 5% compared to 31 ± 6%, p = 0.026). The retrospective clinical study showed that only five mild/moderate adverse events were identified in four patients based on the medical records of 110 patients, including swelling, bony mass, and wound dehiscence. This adverse event occurrence was not affected by gender, age, the dose of filled materials, and operations in the study (p > 0.05). Conclusions: BMP-2-loaded CPC has osteoinductivity and more promising biocompatibility than pure CPC. However, its degradation is slower than CPC. The safety of BMP-2-loaded CPC with 0.5 or 1 mg BMP-2 is promising in oral maxillofacial surgery. Clinical implications: This study confirmed the promising safety of this BMP-2 incorporated CPC used in dental clinical practice, which can promote its reassuring application for dental implant placement in bone insufficient areas. Graphical
- Open Access
Ultrasound-Activated Multifunctional Bioactive Calcium Phosphate Composites for Enhanced Osteosarcoma Treatment
Bone defects caused by surgical interventions and the challenges of tumor recurrence and metastasis due to residual cancer cells significantly complicate the treatment of osteosarcoma (OS). To address these complex clinical challenges, we propose an innovative therapeutic strategy that centers on an ultrasound-activated multifunctional bioactive calcium phosphate (BioCaP) composite. A modified curcumin (mcur)-mediated wet biomimetic mineralization process was used to develop an anticancer-drug-integrated multifunctional BioCaP (mcur@BioCaP), exploring its potential biological effects for OS treatment activated by ultrasound (US). The mcur@BioCaP demonstrates a drug dose-dependent, tailorable alteration in its micro/nanostructure. The US stimulus significantly enhanced this composite to generate reactive oxygen species (ROS) in cancer cells. The results show that the OS cell viability of the mcur@BioCaP with US is 62.2% ± 6.3%, the migration distance is 63.9% ± 6.6%, and the invaded OS cell number is only 57.0 ± 3.7 OS cells per version, which were all significantly lower than US or mcur@BioCaP alone, suggesting that the anticancer, anti-migratory and anti-invasive effects of mcur@BioCaP on OS 143B cells were amplified by ultrasonic stimulation. This amplification can be attributed to the US-activated ROS production from the drug molecules, which regulates the wet biomimetic mineralization of the multifunctional composite. Furthermore, mcur@BioCaP with US increased calcium nodule formation by 1.8-fold, which was significantly higher than mcur@BioCaP or US group, indicating its potential in promoting bone regeneration. The anticancer and osteogenic potentials of mcur@BioCaP were found to be consistent with the mcur concentration in the multifunctional composite. Our research provides a novel therapeutic approach that leverages a multifunctional biomimetic mineral and ultrasonic activation, highlighting its potential applications in OS therapy.
Open AccessUltrasound-Activated Multifunctional Bioactive Calcium Phosphate Composites for Enhanced Osteosarcoma Treatment
Bone defects caused by surgical interventions and the challenges of tumor recurrence and metastasis due to residual cancer cells significantly complicate the treatment of osteosarcoma (OS). To address these complex clinical challenges, we propose an innovative therapeutic strategy that centers on an ultrasound-activated multifunctional bioactive calcium phosphate (BioCaP) composite. A modified curcumin (mcur)-mediated wet biomimetic mineralization process was used to develop an anticancer-drug-integrated multifunctional BioCaP (mcur@BioCaP), exploring its potential biological effects for OS treatment activated by ultrasound (US). The mcur@BioCaP demonstrates a drug dose-dependent, tailorable alteration in its micro/nanostructure. The US stimulus significantly enhanced this composite to generate reactive oxygen species (ROS) in cancer cells. The results show that the OS cell viability of the mcur@BioCaP with US is 62.2% ± 6.3%, the migration distance is 63.9% ± 6.6%, and the invaded OS cell number is only 57.0 ± 3.7 OS cells per version, which were all significantly lower than US or mcur@BioCaP alone, suggesting that the anticancer, anti-migratory and anti-invasive effects of mcur@BioCaP on OS 143B cells were amplified by ultrasonic stimulation. This amplification can be attributed to the US-activated ROS production from the drug molecules, which regulates the wet biomimetic mineralization of the multifunctional composite. Furthermore, mcur@BioCaP with US increased calcium nodule formation by 1.8-fold, which was significantly higher than mcur@BioCaP or US group, indicating its potential in promoting bone regeneration. The anticancer and osteogenic potentials of mcur@BioCaP were found to be consistent with the mcur concentration in the multifunctional composite. Our research provides a novel therapeutic approach that leverages a multifunctional biomimetic mineral and ultrasonic activation, highlighting its potential applications in OS therapy.
- Open Access
- 26 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 11975
Paradox: Curcumin, a Natural Antioxidant, Suppresses Osteosarcoma Cells via Excessive Reactive Oxygen Species
Osteosarcoma (OS) is an aggressive tumor with a rare incidence. Extended surgical resections are the prevalent treatment for OS, which may cause critical-size bone defects. These bone defects lead to dysfunction, weakening the post-surgical quality of patients’ life. Hence, an ideal therapeutic agent for OS should simultaneously possess anti-cancer and bone repair capacities. Curcumin (CUR) has been reported in OS therapy and bone regeneration. However, it is not clear how CUR suppresses OS development. Conventionally, CUR is considered a natural antioxidant in line with its capacity to promote the nuclear translocation of a nuclear transcription factor, nuclear factor erythroid 2 (NRF2). After nuclear translocation, NRF2 can activate the transcription of some antioxidases, thereby circumventing excess reactive oxygen species (ROS) that are deleterious to cells. Intriguingly, this research demonstrated that, in vitro, 10 and 20 μM CUR increased the intracellular ROS in MG-63 cells, damaged cells’ DNA, and finally caused apoptosis of MG-63 cells, although increased NRF2 protein level and the expression of NRF2-regulated antioxidase genes were identified in those two groups.
- 26 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 11975
Open AccessParadox: Curcumin, a Natural Antioxidant, Suppresses Osteosarcoma Cells via Excessive Reactive Oxygen Species
Osteosarcoma (OS) is an aggressive tumor with a rare incidence. Extended surgical resections are the prevalent treatment for OS, which may cause critical-size bone defects. These bone defects lead to dysfunction, weakening the post-surgical quality of patients’ life. Hence, an ideal therapeutic agent for OS should simultaneously possess anti-cancer and bone repair capacities. Curcumin (CUR) has been reported in OS therapy and bone regeneration. However, it is not clear how CUR suppresses OS development. Conventionally, CUR is considered a natural antioxidant in line with its capacity to promote the nuclear translocation of a nuclear transcription factor, nuclear factor erythroid 2 (NRF2). After nuclear translocation, NRF2 can activate the transcription of some antioxidases, thereby circumventing excess reactive oxygen species (ROS) that are deleterious to cells. Intriguingly, this research demonstrated that, in vitro, 10 and 20 μM CUR increased the intracellular ROS in MG-63 cells, damaged cells’ DNA, and finally caused apoptosis of MG-63 cells, although increased NRF2 protein level and the expression of NRF2-regulated antioxidase genes were identified in those two groups.
- Open Access
- 5 May 2023
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 12 (5) , 311-312
Osteosarcoma cells/cell lines are not appropriate for studies on bone regeneration in vitro
Osteosarcoma cells/cell lines are not appropriate for studies on bone regeneration in vitro
- 5 May 2023
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 12 (5) , 311-312
Open AccessOsteosarcoma cells/cell lines are not appropriate for studies on bone regeneration in vitro
Osteosarcoma cells/cell lines are not appropriate for studies on bone regeneration in vitro